AZTR logo

AZITRA INC

AZTRNYSE AMERICAN
🏆 #4979 by market capUS Equity
——
Quote unavailable
🔔
Track AZTR
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
16.6x
Expensive
Otter Score
—
Insufficient data
No chart data available for AZTR.

Trading Snapshot

Day Range
—
52-Week Range
$0.52 – $7.63
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
60.6M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
16.6x
EPS (TTM)
$-2.06
Dividend Yield
—
Dilution (1yr)
+838.0%
AZTR logo

AZITRA INC

AZTR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −0.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +8.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.7M▲ +838.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$2M YoY
StockOtter · stockotter.space

About AZITRA INC

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.